Growing momentum in oncolytic immunotherapy
Recent advances have renewed interest in the potential of oncolytic viruses to treat cancer, including an important new US product approval and the potential for another oncolytic virus‑based therapy to reach the US market in 2027. Alongside direct tumour‑cell killing, increasing understanding of oncolytic virus biology has highlighted their potential to remodel the tumour microenvironment, turn immunologically “cold” tumours “hot” and stimulate local and systemic anti‑tumour immune responses. This provides opportunities both as monotherapy and in combination with other cancer immunotherapies.
Theolytics is pioneering a differentiated approach to oncolytic immunotherapy, developing targeted adenoviral candidates designed for both direct and intravenous delivery and designed for sustained activity within the challenging microenvironment of stroma‑rich tumours. Dense tumour stroma is an important feature of several major and difficult‑to‑treat cancers, including ovarian, colorectal and pancreatic ductal adenocarcinoma, as well as triple‑negative breast cancer.
Theolytics’ lead candidate, THEO‑260, is being evaluated in two clinical trials in patients with advanced ovarian cancer: through intravenous (IV) administration in the OCTOPOD‑IV study in the UK, Spain and Canada (NCT06618235); and through intraperitoneal (IP) administration in the OCTOPOD‑IP study at The University of Texas MD Anderson Cancer Center in the US (NCT07211659).
With funding secured from leading life sciences investors, together with an additional €8 million in non‑dilutive funding from Horizon Europe, the European Union’s flagship research and innovation funding programme, Theolytics is well positioned to advance the clinical development of THEO‑260 and explore the broader potential of its next‑generation oncolytic immunotherapy platform across stroma‑rich solid tumours.
